Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of subcutaneous TQB2922 in recurrent or metastatic head and neck cancer
CTR20261675Phase 2Active
- Sponsor
- China Grand Pharmaceutical and Healthcare Holdings
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tqb2922 in head and neck cancer (HNC), sponsored by China Grand Pharmaceutical and Healthcare Holdings. Started May 2026; status: active.
02
Drugs
tqb2922
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on CTR20261675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261675.